WEBULL
WebtradeDownload

Sysmex (TSE:6869) Rebound Puts Fair Value Back In Focus

Simply Wall St · 2d ago

Sysmex (TSE:6869) has drawn fresh attention after recent share price moves, with the stock last closing at ¥1,879.5. Investors are weighing this shift against its healthcare diagnostics footprint and current earnings profile.

Recent trading has been choppy rather than euphoric, with Sysmex recording a 1 day share price decline of 1.03% but a 90 day share price return of 22.76%. The 1 year total shareholder return of 3.06% contrasts with a 5 year total shareholder return that is down 56.39%, hinting that near term momentum has picked up after a much tougher multi year stretch.

Compare Sysmex's recent swing with other healthcare diagnostics plays by scanning our hand picked list of 10 healthcare AI stocks that are also seeing fresh attention from the market.

Sysmex now trades about 13% below both its intrinsic estimate and analyst target after a strong 90 day rebound. Is that a genuine discount, or is the market pricing ongoing caution correctly?

Most Popular Narrative: 9% Undervalued

Sysmex’s most followed narrative pegs fair value around ¥2,060 per share, which sits above the last close at ¥1,879.5 and frames the recent rebound as only a partial catch up to that estimate.

Ongoing value chain reforms, including a shift towards higher margin product mix, in house production and supply chain optimisation, are aimed at structurally improving gross profit margins and capital efficiency. This can support operating profit and net margins.

See why 2 investors see Sysmex as 9% undervalued.

Result: Fair Value of ¥2,060.7 (UNDERVALUED)

Still, the Sysmex story depends heavily on China not tightening healthcare cost controls further and on recent investments avoiding a scenario in which costs stay high while high margin reagent uptake lags.

Find out about the key risks to this Sysmex narrative.

Another View: What Multiples Say About Sysmex

The DCF work suggests Sysmex trades below an estimate of fair value, but the earnings multiple paints a tougher picture. The stock changes hands at a P/E of 28.7x, compared with a fair ratio of 24.6x, the JP Medical Equipment industry at 16.2x, and peers at 20.7x. That gap points to meaningful valuation risk if sentiment cools, so which signal matters more for you?

To put those P/E gaps in context and see what the numbers imply if the market moves closer to the fair ratio, See what the numbers say about this price — find out in our valuation breakdown.

TSE:6869 P/E Ratio as at Oct 2026
TSE:6869 P/E Ratio as at Oct 2026

Next Steps

Sentiment on Sysmex is mixed, with the rebound clashing against earlier weakness and both risk and reward signals in play. If you want to move quickly and build your own stance using the same underlying flags, start with the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Sysmex?

Do not stop your research at Sysmex. Use the Simply Wall Street Screener to widen your watchlist and pressure test your thinking against fresh opportunities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.